CN115645534A - 治疗或预防皮肤障碍的新型组合物和方法 - Google Patents

治疗或预防皮肤障碍的新型组合物和方法 Download PDF

Info

Publication number
CN115645534A
CN115645534A CN202211246255.7A CN202211246255A CN115645534A CN 115645534 A CN115645534 A CN 115645534A CN 202211246255 A CN202211246255 A CN 202211246255A CN 115645534 A CN115645534 A CN 115645534A
Authority
CN
China
Prior art keywords
rapamycin
skin
cells
solvate
diastereomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211246255.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·赛尔
T·拿卡瑞丽
A·阿扎尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drexel University
Original Assignee
Drexel University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drexel University filed Critical Drexel University
Publication of CN115645534A publication Critical patent/CN115645534A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202211246255.7A 2015-09-24 2016-09-19 治疗或预防皮肤障碍的新型组合物和方法 Pending CN115645534A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562232228P 2015-09-24 2015-09-24
US62/232,228 2015-09-24
PCT/US2016/052442 WO2017053222A1 (en) 2015-09-24 2016-09-19 Novel compositions and methods for treating or preventing dermal disorders
CN201680065172.4A CN108348508A (zh) 2015-09-24 2016-09-19 治疗或预防皮肤障碍的新型组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680065172.4A Division CN108348508A (zh) 2015-09-24 2016-09-19 治疗或预防皮肤障碍的新型组合物和方法

Publications (1)

Publication Number Publication Date
CN115645534A true CN115645534A (zh) 2023-01-31

Family

ID=58387119

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211246255.7A Pending CN115645534A (zh) 2015-09-24 2016-09-19 治疗或预防皮肤障碍的新型组合物和方法
CN201680065172.4A Pending CN108348508A (zh) 2015-09-24 2016-09-19 治疗或预防皮肤障碍的新型组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680065172.4A Pending CN108348508A (zh) 2015-09-24 2016-09-19 治疗或预防皮肤障碍的新型组合物和方法

Country Status (9)

Country Link
US (3) US10695326B2 (https=)
EP (2) EP4729121A2 (https=)
JP (3) JP2018528236A (https=)
KR (1) KR20180081501A (https=)
CN (2) CN115645534A (https=)
AU (1) AU2016325446B2 (https=)
CA (1) CA3037469C (https=)
ES (1) ES3060762T3 (https=)
WO (1) WO2017053222A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
KR20180081501A (ko) * 2015-09-24 2018-07-16 드렉셀유니버시티 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법
WO2018031789A1 (en) * 2016-08-10 2018-02-15 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
CA3115691A1 (en) * 2018-10-11 2020-04-16 Drexel University Methods for treating or preventing skin conditions
US20210353701A1 (en) * 2018-11-02 2021-11-18 Shiseido Company, Ltd. Ultraviolet light-induced inflammation suppressing agent comprising alternative autophagy inducing agent
KR102132921B1 (ko) * 2018-12-13 2020-07-13 영남대학교 산학협력단 조타로리무스를 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046436A1 (en) * 2007-10-04 2009-04-09 Memorial Sloan-Kettering Cancer Center Methods for inhibiting senescence of epithelial cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US20040180430A1 (en) * 1999-09-07 2004-09-16 West Michael D. Methods of restoring telomere length and extending cell lifespan using nuclear transfer
US7026374B2 (en) 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
WO2005010010A1 (en) 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
US20050250805A1 (en) * 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical ointment formulations
CA2601694A1 (en) 2005-03-14 2006-09-21 Macrochem Corporation Enhancement of macrolide penetration through human skin
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
MXPA06008797A (es) * 2006-08-03 2008-02-04 Fernando Ahumada Ayala Preparacion topica para el tratamiento de enfermedades inflamatorias de la piel que contiene sirolimus.
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
WO2008143928A1 (en) 2007-05-15 2008-11-27 Puretech Ventures Methods and compositions for treating skin conditions
EP2362866B1 (en) 2008-11-11 2015-07-08 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
AU2013204219B2 (en) 2009-04-10 2015-05-07 Haiyan Qi Novel anti-aging agents and methods to identify them
AU2010233073B2 (en) 2009-04-10 2014-07-31 Haiyan Qi Novel anti-aging agents and methods to identify them
CA2822746A1 (en) 2009-12-21 2011-06-30 Sarah Bacus Compositions and methods for treatment of vitiligo
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
CA2825786A1 (en) 2011-01-31 2012-08-09 Osaka University Externally-used drug for treating skin disorder and method for producing same
US20130102572A1 (en) 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
CA2854926A1 (en) * 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
US20150202187A1 (en) 2012-06-26 2015-07-23 Sarah Bacus Compositions and methods for treatment of vitiligo
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN105899232A (zh) * 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
US9980976B2 (en) * 2015-02-17 2018-05-29 Northwestern University Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists
KR20180081501A (ko) 2015-09-24 2018-07-16 드렉셀유니버시티 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046436A1 (en) * 2007-10-04 2009-04-09 Memorial Sloan-Kettering Cancer Center Methods for inhibiting senescence of epithelial cells

Also Published As

Publication number Publication date
EP3352755A4 (en) 2019-04-03
AU2016325446B2 (en) 2021-05-13
US20180280362A1 (en) 2018-10-04
JP2022009168A (ja) 2022-01-14
JP7332666B2 (ja) 2023-08-23
CA3037469A1 (en) 2017-03-30
JP2018528236A (ja) 2018-09-27
JP7573078B2 (ja) 2024-10-24
US10695326B2 (en) 2020-06-30
ES3060762T3 (en) 2026-03-30
WO2017053222A1 (en) 2017-03-30
EP3352755A1 (en) 2018-08-01
CN108348508A (zh) 2018-07-31
US20220031673A1 (en) 2022-02-03
HK1258696A1 (en) 2019-11-15
US20200281903A1 (en) 2020-09-10
AU2016325446A1 (en) 2018-04-19
EP4729121A2 (en) 2026-04-22
KR20180081501A (ko) 2018-07-16
JP2023154020A (ja) 2023-10-18
CA3037469C (en) 2024-04-16
US11179374B2 (en) 2021-11-23
EP3352755B1 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
JP7573078B2 (ja) 真皮障害を治療または予防するための新規組成物および方法
Nadal et al. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review
US11957931B2 (en) Compositions and methods for treating vitiligo
US9555034B2 (en) Compositions and methods for treating skin cancer associated diseases
US9358236B2 (en) Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
US10568895B2 (en) Methods and materials for treating calcific aortic valve stenosis
TW201244716A (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
KR20120133389A (ko) 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제
US12465605B2 (en) Methods and materials for gender-dependent treatment of cardiovascular dysfunction
HK1258696B (en) Topical composition comprising rapamycin for use in treating or preventing seborrheic keratosis or actinic keratosis
US12582649B2 (en) Compositions and methods for hair follicle regeneration

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230131

WD01 Invention patent application deemed withdrawn after publication